If you don't mind I have two questions ;
1- from the two future drugs which one is more promising in your opinion ?
2- for patients with no kras wiled mutation is there anything out there that may help them ?
Or future drug ?
1 - That is a really tough question to answer. I have anecdotally heard of complete response patients on both. They are currently going after different patient populations however, so that may be a better way to guide choice than to try to figure out "which is better in general" based upon very limited information. Sym004 is curently being targetted towards as a "second line" therapy patients who had responded to Erbitux or Vectibix and have become resistant - so if you are in that group, sym004 is currently the one to consider. If you are KRAS-wt and considering going on Erbitux as standard care as your first EGFR-inhibitor, that is a time to consider entering the Imprime PGG trial.
2- to correct terminology "KRAS-wild type" is not a mutation, the term "wild-type" = "non-mutated". But I think you are probably asking about options for KRAS-mutated folks. I posted before some preliminary results (first ~20 patients) on "RRx-001" that showed a pretty high response rate even if KRAS-mutated (just search posts for RRx-001). So that is one to consider which has released clinical data. There are others as well which have released less detailed information that appear KRAS-agnostic. In terms of future drugs, many/most immunotherapies will probably not care about KRAS-status. On the flip side - our own Celine appears to be potentially having activity in the NIH TIL trial ---- not only is she KRAS-mut but the TIL they are using for her is actually targetting her KRAS mutant protein!
Hope that helps,
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List